Torrent Pharma-J.B. Chemicals Merger Advances on NCLT Correction Order

Torrent Pharmaceuticals' proposed ₹25,689 crore merger with J.B. Chemicals & Pharmaceuticals has moved forward after the National Company Law Tribunal (NCLT) issued a correction order.

Torrent Pharma recently reported Q2 FY26 revenues of ₹3,302 crore, showing its current scale before integrating J.B. Chemicals.

This correction order signals progress for the merger, though integration challenges and past penalties for J.B. Chemicals will remain key considerations.

NCLT Issues Correction Order

Torrent Pharmaceuticals announced on March 25, 2026, that the National Company Law Tribunal (NCLT), Ahmedabad Bench, issued a correction order regarding the proposed merger of J.B. Chemicals & Pharmaceuticals (Transferor Company) with Torrent Pharmaceuticals (Transferee Company). The correction was dated March 24, 2026, and posted on the NCLT website the following day. This follows an earlier NCLT order on the initial application for the merger.

Merger Progress Accelerates

The NCLT's correction order represents a step forward in the merger process. It brings Torrent Pharmaceuticals and J.B. Chemicals closer to combining into a larger, integrated drug company. The update provides clearer details on parts of the previously approved merger plan.

Deal Background

Torrent Pharmaceuticals, a leading Indian drug maker specializing in cardiovascular, central nervous system (CNS), and gastrointestinal (GI) treatments, announced its plan in June 2025 to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals from KKR for ₹25,689 crore. The deal involves two parts: first, buying a 46.39% stake for ₹11,917 crore, followed by a mandatory open offer and the merger. J.B. Chemicals, known for gastroenterology, hypertension, and dermatology products, will merge into Torrent Pharma. J.B. Chemicals shareholders will receive 51 Torrent Pharma shares for every 100 J.B. Chemicals shares they hold. Based on FY25 data, the combined company is expected to have pro forma revenues above ₹15,000 crore and EBITDA exceeding ₹4,800 crore, making Torrent Pharma a major force in the Indian pharmaceutical market. The NCLT's current order is a key step toward securing all required regulatory approvals for this merger.

Impact of the Correction

This correction order likely adds minor clarifications or tweaks to the merger terms previously approved by the NCLT. It shows progress in meeting regulatory requirements for the deal. The overall plan and strategic goals of the merger remain the same.

Risks to Monitor

J.B. Chemicals has encountered some regulatory hurdles, including an ₹80.81 crore GST penalty that it plans to appeal. The company also conducted a voluntary recall in the U.S. for certain tablets due to an imprinting error, which was deemed low-risk. Merging two different company cultures and operating systems after the deal closes could also create future challenges.

Competitive Landscape

As of July 2024, Torrent Pharmaceuticals ranks as the 6th largest pharmaceutical company in India by market capitalization, alongside peers like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Lupin. The merger with J.B. Chemicals is set to boost Torrent's size, potentially reshaping market competition by forming a more robust, integrated company. This move aligns with a broader trend in the Indian pharmaceutical industry where companies are consolidating to achieve greater market reach and operational efficiency.

What to Watch Next

Investors will closely watch for remaining approvals from regulators like SEBI, the Competition Commission of India (CCI), and the stock exchanges. Updates from the NCLT and Torrent Pharmaceuticals' public filings will be important. How well Torrent integrates J.B. Chemicals' operations and markets will be a key indicator of future success.